Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease

Whole blood samples were collected from patients at baseline, 6 weeks and 8 weeks after induction (Ustekinumab or placebo) therapies for RNA extraction and microarray analysis from patients with moderate-to-severe CD who participated in stelara CD phase 3 studies (UNITI-2). These patients failed conventional therapies previously and largely naive to anti-TNF therapy. We used microarrays to detail the transcriptional programme underlying placebo and stelara treatment in the periphery at WK0, WK6, WK8. A gene expression profiling study was conducted in whole blood samples and samples were collected for RNA extraction and hybridization to microarrays from patients with moderate-to-severe Crohn's disease